Physician profile
Qian Wang
NPI 1619572013
$2,389.48
in general payments reported to CMS, 2019-2025
14 companies · $1,251 in 2025
The $1,251 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $310 · 2024: $828 · 2025: $1,251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,373 · Education: $16.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,372.65 |
| Education | $16.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $944.87 | 2023-2025 | |
| Janssen Biotech, INC. | $400.12 | 2023-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $247.02 | 2024-2025 | Entyvio |
| Ardelyx, INC. | $244.16 | 2024-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.91 | 2024-2025 | Trulance, Xifaxan |
| Gilead Sciences, INC. | $123.84 | 2025 | |
| Phathom Pharmaceuticals, INC. | $105.64 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $34.13 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $32.44 | 2023-2024 | Linzess |
| Aimmune Therapeutics, INC. | $32.33 | 2025 | Vowst, Zenpep |
| Amgen INC. | $18.91 | 2025 | Uplizna |
| Regeneron Healthcare Solutions, INC. | $17.47 | 2023 | Dupixent |
| Celltrion USA INC. | $16.83 | 2024 | Zymfentra |
| Braintree Laboratories, INC. | $16.81 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qian Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.